Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers

Transplant Immunology

Volumn 11, Issue 2, 2003, Pages 163-167

  Bîrsan, Tudor ^a   Dambrin, Camille ^a   Klupp, Jochen ^a   Stalder, Mario ^a   Fitzimmons, William E ^b   Morris, Randall E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

FACS; Leflunomide; Lymphocytes; Malononitrilamides; Non human primates

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; CD11 ANTIGEN; CD40 LIGAND; CELL NUCLEUS ANTIGEN; FAS ANTIGEN; INTERLEUKIN 2 RECEPTOR; MALONONITRILAMIDE; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INTRACELLULAR MEMBRANE; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; NORMAL HUMAN; PRIMATE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION; VOLUNTEER;

ALKYNES; ANIMALS; BIOLOGICAL ASSAY; BLOOD CHEMICAL ANALYSIS; CELL DIVISION; FEMALE; FLOW CYTOMETRY; HUMANS; ISOXAZOLES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; NITRILES; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 0038037898     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(02)00155-7     Document Type: Article

References (9)

1. Silva HT, Morris RE. Leflunomide and malonotrilamides. Am J Med Sci 1997;313:289-301.
2. Barten MJ, Gummert JF, Van Gelder T, Shorthouse R, Morris RE. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: Inhibition by immunosuppressive drugs in vitro. J Immunol Methods 2001;253:95-112.
3. Gummert JF, Barten MJ, Van Gelder T, Billingham ME, Morris RE. Pharmacodynamics of mycophenolic acid in heart allograft recipients: Correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation 2000;70:1038-1049.
4. Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;273:21682-21691.
5. Hermann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000;47:273-289.
6. Slauson SD, Silva HT, Sherwood SW, Morris RE. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett 1999;67:179-183.
7. Gregory CR, Silva HT, Patz JD, Morris RE. Comparative effects of malononitrilamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats. Transplant Proc 1998;30:1047-1048.
8. Chong AS, Huang W, Liu W, et al. In vivo activity of leflunomide: Pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999;68:100-109.
9. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61:635-642.